

## Development of SHIVs for Vaccine Evaluation in NHP

**Date:** Thursday March 17, 2016

**Organizers:**

**Location:** The Muse Hotel  
130 West 46th Street  
New York, NY 10036

Alan Schultz, Division of AIDS, NIAID  
Jeffrey Lifson, Frederick National Laboratory  
Yegor Voronin, Global HIV Vaccine Enterprise

### Agenda Draft

---

<b>8:30 – 8:45</b>	<b>Welcome and Objectives</b>
<b>Block 1:</b>	<b>Applications of SHIVs</b>
	The first thematic block will address SHIVs from the user’s perspective, seeking to define the likely applications of SHIVs, the desirable characteristics of an “ideal SHIV” for these applications, the performance and limitations of SHIVs used to date in this setting, and prioritization of desirable properties to be embodied in “next generation” SHIVs. This block will cover both prophylactic and therapeutic applications.
<b>8:45 – 9:00</b>	<b>Introductory Presentation: Prophylactic applications (Mario Roederer)</b>
<b>9:00 – 10:00</b>	<b>Discussion</b>
<b>10:00 – 10:15</b>	<b>Introductory Presentation: Therapeutic applications (Dan Barouch)</b>
<b>10:15 – 10:45</b>	<b>Discussion</b>
<b>10:45 – 11:15</b>	<i>Coffee break</i>
<b>Block 2:</b>	<b>Generation and Characterization of SHIVs</b>
	The second thematic block will address different aspects of SHIVs themselves (source of incorporated Env sequences [clades, T/F, <i>in vivo</i> NHP adapted, etc], construction, tropism, neutralization profile and <i>in vivo</i> properties in NHP), covering SHIVs used to date and their properties, and the current state of the art in ongoing efforts to develop new SHIVs with more desirable properties.
<b>11:15 – 11:30</b>	<b>Introductory Presentation: Considerations in the Construction and Evaluation of New SHIVs (Brandon Keele)</b>
<b>11:30 – 11:45</b>	<b>Participant Presentation: Novel approach to creating SHIVs (George Shaw)</b>
<b>11:45 – 12:30</b>	<b>Discussion</b>
<b>12:30 – 1:30</b>	<i>Lunch break</i>

---

*Agenda draft (continued)*

---

**Block 3: SHIV Challenge Stocks**

The third thematic block will focus on the alternative methods for production and characterization of challenge stocks for use in studies in vivo in NHP (transfection, in vitro expansion in primary PBMC (macaque, human), in vitro expansion in cell lines, in vivo expansion in NHP), and the implications of stock production by these different.

**1:30 – 1:45**      **Introductory Presentation: Generation and Characterization of SHIV Challenge Stocks (Greg Del Prete)**

**1:45 – 2:45**      **Discussion**

---

**2:45 – 3:15**      *Coffee break*

---

**3:15 – 4:30**      **Final wrap-up session**

---